Key result
Renin rs2368564 AA genotype linked to ~4.1-fold higher odds of in-stent restenosis after DES.
Why the study?
This study investigated RAAS gene polymorphisms as possible genetic risk factors for in-stent restenosis development in patients with drug-eluting stents.
Are renin-angiotensin-aldosterone system (RAAS) gene polymorphisms associated with the development of in-stent restenosis in patients with stable coronary artery disease?
Case-Control (n=175)
Are renin-angiotensin-aldosterone system (RAAS) gene polymorphisms associated with the development of in-stent restenosis in patients with stable coronary artery disease?
Answers are grounded in this paper and cite their sources.
Specific RAAS gene polymorphisms are associated with the risk of in-stent restenosis after drug-eluting stent implantation, suggesting a potential role for genetic profiling in risk stratification.
This study investigated the renin-angiotensin-aldosterone system (RAAS) gene polymorphisms as possible genetic risk factors for the restenosis development in patients with drug-eluting stents. 113 participants had coronary artery disease and underwent stenting. The control group consisted of 62 individuals with intact coronary arteries. Patients were divided into two groups: with in-stent restenosis (ISR) and without it. The patients with ISR were classified into subgroups by the terms of the restenosis development and age. Real-time PCR and Restriction Fragment Length Polymorphism-PCR were used to genotype the study participants for RAAS gene polymorphisms. We found that the development of restenosis is generally associated with the minor A allele for renin (REN) rs2368564 and the major TT genotype for angiotensinogen (AGT) rs699. The heterozygous genotype for AGT rs4762 acts as a protective marker. A minor A allele for angiotensin II type 2 receptor (AGTR2) rs1403543 is associated with a risk of restenosis in people under 65 years old. Among patients with the early ISR, heterozygotes for angiotensin II type 1 receptor (AGTR1) rs5186 are more frequent, as well as A allele carriers for AGTR2 rs1403543. A minor homozygous genotype for REN rs41317140 and heterozygous genotype for aldosterone synthase (CYP11B2) rs1799998 are predisposed to the late restenosis. Thus, to choose the effective treatment tactics for patients with coronary artery disease, it is necessary to genotype patients for the RAAS polymorphisms, which, along with age and clinical characteristics, will allow a comprehensive assessment of the risk of the restenosis development after stenting.
No takes yet. Share an insight, caveat, or question.
Азова et al. (2021) conducted a case-control in In-stent restenosis after coronary artery disease (n=175). REN rs2368564 AA genotype (minor allele) vs. Absence of AA genotype / non-restenosis was evaluated on Angiographic in-stent restenosis (stenosis of more than 50% of the target vessel) (OR 4.062, 95% CI 1.758-9.382, p=0.0004). The minor AA genotype for the renin rs2368564 polymorphism was significantly associated with an increased risk of in-stent restenosis in patients with stable coronary artery disease after drug-eluting stent implantation (OR 4.062).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: